FDA approves Lundbeck's intravenous migraine prevention drug Vyepti, to launch in April 2020 Medical Dialogues Bureau23 Feb 2020 11:30 AM ISTDeerfield: Lundbeck announced that VYEPTI™ (eptinezumab-jjmr) has been approved by the U.S. Food and Drug Administration (FDA) for the preventive...